Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C106428
http://purl.obolibrary.org/obo/NCIT_C106428
|
|---|---|
| Preferred Name | Anlotinib Hydrochloride |
| Definitions |
The hydrochloride salt form of anlotinib, a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, anlotininib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | The hydrochloride salt form of anlotinib, a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, anlotininib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth. |
|---|---|
| prefLabel | Anlotinib Hydrochloride
|
| label | Anlotinib Hydrochloride
|
| NCI_META_CUI | CL447782
|
| PDQ_Closed_Trial_Search_ID | 749736
|
| code | C106428
|
| Has_Target | |
| prefixIRI | NCIT:C106428
|
| in_subset |
See more
See less
|
| Display_Name | Anlotinib Hydrochloride
|
| Preferred_Name | Anlotinib Hydrochloride
|
| FDA_UNII_Code | A3749M6582
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Anlotinib Hydrochloride
|
| CAS_Registry | 1360460-82-7
|
| NCI_Drug_Dictionary_ID | 749736
|
| Has_Free_Acid_Or_Base_Form | |
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 749736
|
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |